Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc.

Cystic Fibrosis

$9.5B US CF therapeutics market 2023

Disease Overview

Cystic fibrosis is an autosomal recessive disease caused by mutations in the CFTR gene, leading to defective chloride transport, thick mucus accumulation, recurrent pulmonary infections, pancreatic insufficiency and progressive lung damage. The most common mutation is F508del, present in roughly 90% of US patients on at least one allele. CFTR modulator therapy has transformed the disease from a pediatric mortality condition into a chronically managed adult illness for most patients.

Competitive Landscape

At deal close (March 2017), Vertex effectively owned the CFTR modulator class with Kalydeco (ivacaftor, approved 2012) and Orkambi (lumacaftor/ivacaftor, 2015), with Symdeko (tezacaftor/ivacaftor) under FDA review and the elexacaftor triple combination (later Trikafta) in Phase 3. Concert's CTP-656 was the only credible direct-acting potentiator competitor in development — a deuterated version of ivacaftor with a longer half-life enabling once-daily dosing. Leerink analysts told Fierce Biotech the $250M deal was a positive for Vertex because it removed a potential competitor and gave Vertex a next-generation potentiator to extend the franchise into once-daily triple regimens. Concert shares jumped 34.7% on the news per C&EN. The deal mattered because it consolidated CFTR modulator innovation under a single sponsor: Trikafta launched in October 2019 and reached $8.9B in 2023 sales (Fierce Pharma), validating the strategic logic. Galapagos and AbbVie were the other notable challengers in CFTR modulator development at the time but ultimately failed to deliver competitive late-stage assets, leaving Vertex effectively unchallenged in CF through the deutivacaftor (VX-561) era. [https://www.fiercebiotech.com/biotech/vertex-concert-orchestrate-250m-phase-2-cf-drug-deal]